Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 800-807

  Jansson, Johan ^a,b   Hsu, Yu Chiao ^a   Kuzin, Igor I ^a   Campbell, Andrew ^a   Mullen, Craig A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplantation; Cancer immunology; Chemotherapy; Graft versus host disease; Graft versus leukemia effect

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GRAFT VERSUS LEUKEMIA EFFECT; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 79955582370     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.018     Document Type: Article

References (32)

1. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
2. Bhojwani D., Kang H., Moskowitz N.P., Min D.J., Lee H., Potter J.W., et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006, 108:711-717.
3. Pulsipher M.A., Bader P., Klingebiel T., Cooper L.J. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2009, 15:62-71.
4. Mehta P.A., Davies S.M. Allogeneic transplantation for childhood ALL. Bone Marrow Transplant 2008, 41:133-139.
5. Collins R.H., Goldstein S., Giralt S., Levine J., Porter D., Drobyski W., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000, 26:511-516.
6. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86:2041-2050.
7. Shand J.C., Jansson J., Hsu Y.C., Campbell A., Mullen C.A. Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant. Cancer Immunol Immunother 2010, 59:1633-1644.
8. Flotho C., Coustan-Smith E., Pei D., Iwamoto S., Song G., Cheng C., et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006, 108:1050-1057.
9. Holleman A., den Boer M.L., de Menezes R.X., Cheok M.H., Cheng C., Kazemier K.M., et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006, 107:769-776.
10. Holleman A., den Boer M.L., Kazemier K.M., Beverloo H.B., von Bergh A.R., Janka-Schaub G.E., et al. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 2005, 106:1817-1823.
11. Meyer L.H., Karawajew L., Schrappe M., Ludwig W.D., Debatin K.M., Stahnke K., et al. Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. Blood 2006, 107:4524-4531.
12. Troeger A., Schmitz I., Siepermann M., Glouchkova L., Gerdemann U., Janka-Schaub G.E., et al. Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood 2007, 110:384-387.
13. Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007, 92:1043-1050.
14. Holleman A., den Boer M.L., Kazemier K.M., Janka-Schaub G.E., Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003, 102:4541-4546.
15. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
16. Young F.M., Campbell A., Emo K.L., Jansson J., Wang P.-Y., Jordan C.T., et al. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant 2008, 14:622-630.
17. Anderson L.D., Savary C.A., Mullen C.A. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000, 95:2426-2433.
18. Anderson L.D., Mori S., Mann S., Savary C.A., Mullen C.A. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 2000, 60:5797-5802.
19. Mori S., El-Baki H., Mullen C.A. An analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 31:865-875.
20. Mullen C.A. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation. Leuk Lymphoma 2002, 43:503-510.
21. Mundhada S., Shaw J., Mori S., Savary C.A., Mullen C.A. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses. Leuk Lymphoma 2005, 46:571-580.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
23. Swerts K., De Moerloose B., Dhooge C., Laureys G., Benoit Y., Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukemia. Eur J Cancer 2006, 42:295-309.
24. Steinbach D., Wittig S., Cario G., Viehmann S., Mueller A., Gruhn B., et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003, 102:4493-4498.
25. Majlessipour F., Kwock R., Martin-Aragon S., Weinberg K.I., Avramis V.I. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and l-asparaginase: evaluation of cross-resistance to other treatment modalities. Anticancer Res 2001, 21:11-22.
26. Fichtner I., Paal K., Borgmann A., Badiali L., Wurm R., Henze G. Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias - correlation to the expression of multidrug resistance proteins. Anticancer Res 2003, 23:2657-2664.
27. Lu C., El-Deiry W.S. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009, 14:597-606.
28. Shank-Calvo J.A., Draheim K., Bhasin M., Kelliher M.A. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene 2006, 25:3023-3031.
29. Bianchi T., Rufer N., MacDonald H.R., Migliaccio M. The tumor suppressor p16Ink4a regulates T lymphocyte survival. Oncogene 2006, 25:4110-4115.
30. Ayello J., van de Ven C., Fortino W., Wade-Harris C., Satwani P., Baxi L., et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant 2006, 12:608-622.
31. Phillips J.H., Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986, 164:814-825.
32. Kim G.G., Donnenberg V.S., Donnenberg A.D., Gooding W., Whiteside T.L. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4h 51Cr-release assay. J Immunol Methods 2007, 325:51-66.